Leukapheresis Market Size, Share, Trends, Growth Outlook

Leukapheresis Market is estimated to increase at a Compounded Annual Growth Rate of 8.5% CAGR over the forecast period from 2024 to 2030

The Leukapheresis Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Devices, Disposables), By Application (Research, Therapeutic), By Method (Centrifugation, Membrane Separation, Selective Adsorption), By End-User (Hospitals & Transfusion Centers, Component Providers & Blood Centers, Research Institutes, Pharmaceutical Companies), By Indication (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma, Hepatocellular Carcinoma, Pancreatic Cancer, Others).

An Introduction to Leukapheresis Market in 2024

Leukapheresis is a therapeutic procedure used to selectively remove leukocytes, or white blood cells, from the peripheral blood of patients for therapeutic or research purposes. In 2024, leukapheresis continues to play a crucial role in the treatment of hematological disorders, autoimmune diseases, and transplantation, as well as in cell therapy and immunotherapy applications. During leukapheresis, blood is withdrawn from the patient through a central venous catheter or peripheral vein, passed through a cell separation device, and separated into its components using centrifugation or filtration techniques. Leukocytes are then selectively collected or discarded based on their physical properties or surface markers, while the remaining blood components are returned to the patient's circulation. Leukapheresis enables the removal of excess or abnormal leukocytes, such as in leukocytosis, leukemia, or graft-versus-host disease (GVHD), while preserving other blood components, including red blood cells, platelets, and plasma. Additionally, leukapheresis serves as a valuable tool for harvesting specific leukocyte subsets, such as monocytes, lymphocytes, or dendritic cells, for cell-based therapies, immune modulation, and research applications. As our understanding of immune function and cell-based therapies continues to advance, leukapheresis remains a versatile and indispensable technique for manipulating immune cell populations, treating hematological disorders, and advancing therapeutic interventions aimed at restoring immune homeostasis and combating disease.

Market Trend: Increasing Utilization of Leukapheresis in Cell-Based Therapies

A prominent trend in the leukapheresis market is the increasing utilization of leukapheresis procedures in cell-based therapies. As cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy and stem cell transplantation, gain traction in the treatment of various diseases, including cancer, autoimmune disorders, and hematologic conditions, the demand for leukapheresis procedures to collect specific subsets of blood cells is on the rise. Leukapheresis plays a crucial role in isolating and harvesting therapeutic cell populations, such as T-cells or stem cells, from the patient's blood, enabling their further processing and infusion back into the patient for therapeutic purposes. This trend underscores the integral role of leukapheresis in the rapidly expanding field of cell-based therapies and highlights the importance of efficient and reliable cell collection techniques.

Market Driver: Growing Incidence of Blood Disorders and Hematologic Malignancies

A key driver fueling the demand for leukapheresis procedures is the growing incidence of blood disorders and hematologic malignancies worldwide. Conditions such as leukemia, lymphoma, multiple myeloma, and various autoimmune disorders require intensive treatments, including chemotherapy, radiation therapy, and hematopoietic stem cell transplantation. Leukapheresis is often employed as a preparatory step in these treatments to collect peripheral blood stem cells or specific immune cell subsets for autologous or allogeneic transplantation. With an aging population and increasing exposure to environmental risk factors, the prevalence of blood-related disorders is expected to rise, driving the need for leukapheresis procedures as an essential component of treatment protocols.

Market Opportunity: Expansion of Leukapheresis Services in Emerging Markets

A significant opportunity for the leukapheresis market lies in the expansion of leukapheresis services in emerging markets. While leukapheresis procedures are well-established in developed regions, such as North America and Europe, there is growing potential for market penetration in emerging economies across Asia-Pacific, Latin America, and the Middle East. Factors such as improving healthcare infrastructure, rising healthcare expenditure, and increasing awareness about advanced treatment options contribute to the growing demand for leukapheresis services in these regions. Moreover, the prevalence of hematologic disorders and the unmet need for specialized treatments present an opportunity for leukapheresis service providers to establish a presence and cater to the evolving healthcare needs of these markets. Strategic partnerships, technology transfer initiatives, and targeted marketing efforts are essential to capitalize on this opportunity and ensure sustainable growth in emerging markets.

Leukapheresis Market Share Analysis: Leukapheresis for Therapeutic Applications is the fastest growing segment over the forecast period to 2030

Among the segments listed, Leukapheresis for Therapeutic Applications is experiencing the most rapid growth in the market. This growth is driven by several key factors. Firstly, leukapheresis is a critical component of therapeutic strategies for various hematological malignancies and solid tumors. It involves the selective removal of leukocytes from the patient's blood, which can be used for further processing, such as immune cell therapy or stem cell transplantation. The increasing prevalence of hematological cancers, including acute lymphocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and multiple myeloma, as well as solid tumors like hepatocellular carcinoma and pancreatic cancer, has driven the demand for leukapheresis as an adjunctive therapy. Secondly, advancements in leukapheresis technology, including the development of more efficient and versatile devices and disposables, have improved the efficacy and safety of therapeutic leukapheresis procedures. These technological advancements have enabled higher yields of target cells, reduced procedure times, and enhanced patient comfort, leading to improved treatment outcomes and patient satisfaction. Thirdly, the growing adoption of personalized medicine and targeted therapies in oncology has increased the demand for leukapheresis as a means of obtaining patient-specific cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapy and dendritic cell vaccines. Leukapheresis plays a crucial role in isolating and enriching specific immune cell populations for ex vivo manipulation and reinfusion into patients, thereby offering a promising avenue for precision cancer treatment. Additionally, the expanding applications of leukapheresis in autoimmune diseases, graft-versus-host disease (GVHD), and transplant immunotherapy further contribute to market growth. With ongoing advancements in therapeutic leukapheresis techniques and increasing adoption by hospitals, transfusion centers, and pharmaceutical companies, the segment is poised for sustained rapid growth in the Leukapheresis Market.

Leukapheresis Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAsahi Kasei Corp, Caltag Medsystems Ltd, Charles River Laboratories International Inc, Discovery Life Sciences Inc, Fresenius SE & Co. KGaA, Haemonetics Corp, Lonza Group AG, Macopharma SA, Miltenyi Biotec GmbH, StemExpress LLC, Terumo BCT Inc, ZenBio Inc

Leukapheresis Market Segmentation

By Product
Devices
-Centrifugal Devices
-Membrane Separators
Disposables
By Application
Research
Therapeutic
By Method
Centrifugation
Membrane Separation
Selective Adsorption
By End-User
Hospitals & Transfusion Centers
Component Providers & Blood Centers
Research Institutes
Pharmaceutical Companies
By Indication
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin’s Lymphoma
Multiple Myeloma
Hepatocellular Carcinoma
Pancreatic Cancer
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Leukapheresis Market Companies

Asahi Kasei Corp
Caltag Medsystems Ltd
Charles River Laboratories International Inc
Discovery Life Sciences Inc
Fresenius SE & Co. KGaA
Haemonetics Corp
Lonza Group AG
Macopharma SA
Miltenyi Biotec GmbH
StemExpress LLC
Terumo BCT Inc
ZenBio Inc

Reasons to Buy the Leukapheresis Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Leukapheresis Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Leukapheresis Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Leukapheresis Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Leukapheresis Market Size Outlook, $ Million, 2021 to 2030
3.2 Leukapheresis Market Outlook by Type, $ Million, 2021 to 2030
3.3 Leukapheresis Market Outlook by Product, $ Million, 2021 to 2030
3.4 Leukapheresis Market Outlook by Application, $ Million, 2021 to 2030
3.5 Leukapheresis Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Leukapheresis Industry
4.2 Key Market Trends in Leukapheresis Industry
4.3 Potential Opportunities in Leukapheresis Industry
4.4 Key Challenges in Leukapheresis Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Leukapheresis Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Leukapheresis Market Outlook by Segments
7.1 Leukapheresis Market Outlook by Segments, $ Million, 2021- 2030
By Product
Devices
-Centrifugal Devices
-Membrane Separators
Disposables
By Application
Research
Therapeutic
By Method
Centrifugation
Membrane Separation
Selective Adsorption
By End-User
Hospitals & Transfusion Centers
Component Providers & Blood Centers
Research Institutes
Pharmaceutical Companies
By Indication
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin’s Lymphoma
Multiple Myeloma
Hepatocellular Carcinoma
Pancreatic Cancer
Others

8 North America Leukapheresis Market Analysis and Outlook To 2030
8.1 Introduction to North America Leukapheresis Markets in 2024
8.2 North America Leukapheresis Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Leukapheresis Market size Outlook by Segments, 2021-2030
By Product
Devices
-Centrifugal Devices
-Membrane Separators
Disposables
By Application
Research
Therapeutic
By Method
Centrifugation
Membrane Separation
Selective Adsorption
By End-User
Hospitals & Transfusion Centers
Component Providers & Blood Centers
Research Institutes
Pharmaceutical Companies
By Indication
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin’s Lymphoma
Multiple Myeloma
Hepatocellular Carcinoma
Pancreatic Cancer
Others

9 Europe Leukapheresis Market Analysis and Outlook To 2030
9.1 Introduction to Europe Leukapheresis Markets in 2024
9.2 Europe Leukapheresis Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Leukapheresis Market Size Outlook by Segments, 2021-2030
By Product
Devices
-Centrifugal Devices
-Membrane Separators
Disposables
By Application
Research
Therapeutic
By Method
Centrifugation
Membrane Separation
Selective Adsorption
By End-User
Hospitals & Transfusion Centers
Component Providers & Blood Centers
Research Institutes
Pharmaceutical Companies
By Indication
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin’s Lymphoma
Multiple Myeloma
Hepatocellular Carcinoma
Pancreatic Cancer
Others

10 Asia Pacific Leukapheresis Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Leukapheresis Markets in 2024
10.2 Asia Pacific Leukapheresis Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Leukapheresis Market size Outlook by Segments, 2021-2030
By Product
Devices
-Centrifugal Devices
-Membrane Separators
Disposables
By Application
Research
Therapeutic
By Method
Centrifugation
Membrane Separation
Selective Adsorption
By End-User
Hospitals & Transfusion Centers
Component Providers & Blood Centers
Research Institutes
Pharmaceutical Companies
By Indication
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin’s Lymphoma
Multiple Myeloma
Hepatocellular Carcinoma
Pancreatic Cancer
Others

11 South America Leukapheresis Market Analysis and Outlook To 2030
11.1 Introduction to South America Leukapheresis Markets in 2024
11.2 South America Leukapheresis Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Leukapheresis Market size Outlook by Segments, 2021-2030
By Product
Devices
-Centrifugal Devices
-Membrane Separators
Disposables
By Application
Research
Therapeutic
By Method
Centrifugation
Membrane Separation
Selective Adsorption
By End-User
Hospitals & Transfusion Centers
Component Providers & Blood Centers
Research Institutes
Pharmaceutical Companies
By Indication
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin’s Lymphoma
Multiple Myeloma
Hepatocellular Carcinoma
Pancreatic Cancer
Others
12 Middle East and Africa Leukapheresis Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Leukapheresis Markets in 2024
12.2 Middle East and Africa Leukapheresis Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Leukapheresis Market size Outlook by Segments, 2021-2030
By Product
Devices
-Centrifugal Devices
-Membrane Separators
Disposables
By Application
Research
Therapeutic
By Method
Centrifugation
Membrane Separation
Selective Adsorption
By End-User
Hospitals & Transfusion Centers
Component Providers & Blood Centers
Research Institutes
Pharmaceutical Companies
By Indication
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin’s Lymphoma
Multiple Myeloma
Hepatocellular Carcinoma
Pancreatic Cancer
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Asahi Kasei Corp
Caltag Medsystems Ltd
Charles River Laboratories International Inc
Discovery Life Sciences Inc
Fresenius SE & Co. KGaA
Haemonetics Corp
Lonza Group AG
Macopharma SA
Miltenyi Biotec GmbH
StemExpress LLC
Terumo BCT Inc
ZenBio Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Devices
-Centrifugal Devices
-Membrane Separators
Disposables
By Application
Research
Therapeutic
By Method
Centrifugation
Membrane Separation
Selective Adsorption
By End-User
Hospitals & Transfusion Centers
Component Providers & Blood Centers
Research Institutes
Pharmaceutical Companies
By Indication
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin’s Lymphoma
Multiple Myeloma
Hepatocellular Carcinoma
Pancreatic Cancer
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)